Introduction Olaparib is an oral anticancer drug that belongs to the poly ADP-ribose polymerase inhibitor class, commonly called PARP inhibitors. It is marketed under the brand name Lynparza. Olaparib is an important targeted anticancer drug used in cancers with defects in DNA repair pathways, especially BRCA1, BRCA2, and other homologous recombination repair gene abnormalities. The … Read more
Introduction Kisqali is the brand name of ribociclib, an oral targeted anticancer drug used in hormone receptor-positive, HER2-negative breast cancer. It belongs to the class of cyclin-dependent kinase 4 and 6 inhibitors, commonly called CDK4/6 inhibitors. Kisqali is important in oncology pharmacology because it targets the cell cycle machinery that allows cancer cells to divide … Read more
Introduction Alpelisib is an oral targeted anticancer drug that belongs to the class of phosphatidylinositol-3-kinase inhibitors. It is mainly known as a selective PI3K alpha inhibitor and is used in diseases driven by activating mutations in the PIK3CA gene. In oncology, alpelisib is used in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated … Read more
